Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and PK Study of Revumenib in Acute Leukemia
NCT05406817Phase 1Completed
- Sponsor
- Syndax Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of revumenib in acute leukemia, sponsored by Syndax Pharmaceuticals. Primary endpoints: Percentage of Dose Excreted in Urine, Percentage of Dose Excreted in Feces and 4 more. Started Aug 2022; status: completed.
02
Drugs
revumenib
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT05406817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05406817.